307 filings
Page 10 of 16
8-K
s1ra9dqj
1 Apr 16
Amicus Therapeutics Receives Positive CHMP Opinion for Approval of Migalastat in Patients with Fabry Disease in European Union
12:00am
8-K
usf2 jpm2
15 Mar 16
Departure of Directors or Certain Officers
12:00am
8-K
pwz5r4
3 Mar 16
Amicus Therapeutics Highlights New Phase 3 Fabry Data and Preclinical Pompe Data at WORLDSymposium™ 2016
12:00am
8-K
pbq5v7md05m
26 Feb 16
Entry into a Material Definitive Agreement
12:00am
8-K
mo8 cmvjax7051rtr4
26 Feb 16
Amicus Therapeutics Announces Full-Year 2015
12:00am
8-K
0q1q 0rjwwzoc6vox
22 Feb 16
Entry into a Material Definitive Agreement
12:00am
8-K
tykb2cc
11 Jan 16
Amicus Therapeutics Provides Full-Year 2016 Strategic Outlook and Financial Guidance
12:00am
8-K
yk2xe 8822i
3 Nov 15
Amicus Therapeutics Announces Third Quarter 2015 Financial Results and Corporate Updates
12:00am
8-K
cdnkp83237czgfmkrjd
1 Oct 15
Entry into a Material Definitive Agreement
12:00am
8-K
c3u7622
30 Sep 15
Entry into a Material Definitive Agreement
12:00am
8-K
l20o2 wt9
14 Sep 15
Entry into a Material Definitive Agreement
12:00am
8-K
503bqlwj
3 Sep 15
Entry into a Material Definitive Agreement
12:00am
8-K
hko2 t502z
31 Aug 15
Amicus Therapeutics to Acquire
12:00am
8-K
1c4dms0
5 Aug 15
Amicus Therapeutics Announces Second Quarter 2015 Financial Results and Corporate Updates
12:00am
8-K
3w3ecw70 gf8ktumpg5
12 Jun 15
Amicus Therapeutics Announces Public
12:00am
8-K
yej8237hu7ipat7o
10 Jun 15
Amicus Therapeutics Strengthens Executive Leadership Team
12:00am
8-K
o72zpv3zvmur8
4 Jun 15
Amicus Therapeutics Submits Marketing Authorization Application (MAA) for Full Approval of Fabry Monotherapy Galafold™ (Migalastat) in European Union
12:00am
8-K
cntdnl 0p6apht53
19 May 15
Other Events
12:00am
8-K
ogejurtb9m54vjj
5 May 15
Amicus Therapeutics Announces First Quarter 2015 Financial Results and Corporate Updates
12:00am
8-K
v7p rj7o4z
28 Apr 15
Entry into a Material Definitive Agreement
12:00am